“Fed Proof” Your Bank Account with THESE 4 Simple Steps

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

Muna Bhanji Biography and Net Worth

Director of Veracyte

Muna Bhanji joined the Veracyte board of directors in 2021. Ms. Bhanji has more than 30 years of strategic and operational experience in the biopharmaceutical industry. She is the Founder and President of Tiba Global Access LLC, an independent senior advisory/consultancy focused on commercialization and market access strategy development, serving the biopharmaceutical industry. She built her career at Merck & Company, Inc., serving most recently as Senior Vice President of Global Market Access & Policy, Global Human Health. In that role, she developed pharmaceutical access and affordability strategies in a highly regulated environment, driving access to medicines in the United States and globally. Ms. Bhanji serves on the boards of biopharmaceutical companies Ardelyx, Intellia and Cytokinetics, Inc., as well as the nonprofit organization Corus International. She previously served on the board of Possible Health, a non-profit with ties to Nepal that delivers affordable and high-quality care to rural and underserved communities, and of the Foundation of Managed Care Pharmacy, which is the research, educational, and philanthropic arm of the Academy of Managed Care Pharmacy. Ms. Bhanji earned her B.S. in Pharmacy from Rutgers University and an M.B.A. from St. Joseph’s University.

What is Muna Bhanji's net worth?: The estimated net worth of Muna Bhanji is at least $830,393.70 as of June 10th, 2024. Ms. Bhanji owns 23,105 shares of Veracyte stock worth more than $830,394 as of November 15th. This net worth estimate does not reflect any other assets that Ms. Bhanji may own. Learn More about Muna Bhanji's net worth.
How do I contact Muna Bhanji?: The corporate mailing address for Ms. Bhanji and other Veracyte executives is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. Veracyte can also be reached via phone at (650) 243-6300 and via email at [email protected]. Learn More on Muna Bhanji's contact information.
Has Muna Bhanji been buying or selling shares of Veracyte?: Muna Bhanji has not been actively trading shares of Veracyte during the last ninety days. Most recently, Muna Bhanji sold 3,870 shares of the business's stock in a transaction on Monday, June 10th. The shares were sold at an average price of $20.32, for a transaction totalling $78,638.40. Following the completion of the sale, the director now directly owns 23,105 shares of the company's stock, valued at $469,493.60. Learn More on Muna Bhanji's trading history.
Who are Veracyte's active insiders?: Veracyte's insider roster includes Bonnie Anderson (Insider), Muna Bhanji (Director), Rebecca Chambers (Exec. VP & CFO ), Karin Eastham (Director), Jens Holstein (Director), Evan Jones (Director), Giulia Kennedy (Insider), John Leite (Chief Commercial Officer, CLIA Business), and Marc Stapley (CEO & Director ). Learn More on Veracyte's active insiders.
Are insiders buying or selling shares of Veracyte?: In the last year, insiders at the biotechnology company sold shares 11 times. They sold a total of 63,827 shares worth more than $1,779,423.17. The most recent insider tranaction occured on September, 19th when Director Evan/ Fa Jones sold 5,173 shares worth more than $182,244.79. Insiders at Veracyte own 1.3% of the company. Learn More about insider trades at Veracyte.
Information on this page was last updated on 9/19/2024.

Muna Bhanji Insider Trading History at Veracyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/10/2024	Sell	3,870	$20.32	$78,638.40	23,105
5/28/2024	Sell	1,539	$21.00	$32,319.00	26,975
6/16/2023	Sell	5,893	$26.44	$155,810.92	28,514
5/30/2023	Sell	1,539	$25.91	$39,875.49	24,733

Muna Bhanji Buying and Selling Activity at Veracyte

Veracyte Company Overview

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Today's Range

Now: $35.94

$35.37

$37.76

50 Day Range

MA: $33.92

$28.57

$39.53

2 Week Range

Now: $35.94

$18.61

$41.43

Volume

1,626,863 shs

Average Volume

771,503 shs

Market Capitalization

$2.79 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.67